A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity

J. W. Hong, J. K. Park, C. Y. Lim, S. W. Kim, Y. S. Chung, S. W. Kim, E. J. Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Administration of recombinant human growth hormone (rhGH) in obesity has been known to lead to a decrease in visceral adiposity and an increase in lean body mass. Most studies have used supraphysiological doses of rhGH, which were administered daily or every other day. We aimed to evaluate whether weekly administered low dose of sustained-release rhGH (SR-rhGH) could play a therapeutic role in the treatment of abdominal obesity. Prospective, single-arm, open-label, multicenter pilot study was carried out. Participants were 26 adults aged 4065 years old with abdominal obesity (male: waist circumference >90cm, female: waist circumference >85cm). The subjects were given 3mg of SR-rhGH, administered subcutaneously, weekly for 26 weeks. SR-rhGH treatment for 26 weeks increased the IGF-1 level by 56.53±76.09g/l (SDS 0.77±1.12) compared to the baseline (p=0.0022). After 26 weeks, SR-rhGH treatment reduced abdominal visceral adipose tissue (VAT) (140.35±75.97 to 128.43±73.85cm 2, p=0.0038). Average waist circumference decreased from 96.25±6.41 to 91.93±6.13cm (p<0.0001) after treatment. However, body weight or lean body mass did not show any significant change. In conclusion, SR-rhGH treatment for 26 weeks reduced abdominal visceral fat and waist circumference without severe adverse events. Further studies may be considered on the role of weekly administered SR-rhGH as a treatment for abdominal obesity.

Original languageEnglish
Pages (from-to)956-961
Number of pages6
JournalHormone and Metabolic Research
Volume43
Issue number13
DOIs
Publication statusPublished - 2011 Nov 9

Fingerprint

Intra-Abdominal Fat
Human Growth Hormone
Abdominal Obesity
Waist Circumference
Growth Hormone
Fats
Insulin-Like Growth Factor I
Abdominal Fat
Labels
Adiposity
Tissue
Multicenter Studies
Obesity
Body Weight
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hong, J. W. ; Park, J. K. ; Lim, C. Y. ; Kim, S. W. ; Chung, Y. S. ; Kim, S. W. ; Lee, E. J. / A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity. In: Hormone and Metabolic Research. 2011 ; Vol. 43, No. 13. pp. 956-961.
@article{570a18c091724489b964fb35729881ed,
title = "A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity",
abstract = "Administration of recombinant human growth hormone (rhGH) in obesity has been known to lead to a decrease in visceral adiposity and an increase in lean body mass. Most studies have used supraphysiological doses of rhGH, which were administered daily or every other day. We aimed to evaluate whether weekly administered low dose of sustained-release rhGH (SR-rhGH) could play a therapeutic role in the treatment of abdominal obesity. Prospective, single-arm, open-label, multicenter pilot study was carried out. Participants were 26 adults aged 4065 years old with abdominal obesity (male: waist circumference >90cm, female: waist circumference >85cm). The subjects were given 3mg of SR-rhGH, administered subcutaneously, weekly for 26 weeks. SR-rhGH treatment for 26 weeks increased the IGF-1 level by 56.53±76.09g/l (SDS 0.77±1.12) compared to the baseline (p=0.0022). After 26 weeks, SR-rhGH treatment reduced abdominal visceral adipose tissue (VAT) (140.35±75.97 to 128.43±73.85cm 2, p=0.0038). Average waist circumference decreased from 96.25±6.41 to 91.93±6.13cm (p<0.0001) after treatment. However, body weight or lean body mass did not show any significant change. In conclusion, SR-rhGH treatment for 26 weeks reduced abdominal visceral fat and waist circumference without severe adverse events. Further studies may be considered on the role of weekly administered SR-rhGH as a treatment for abdominal obesity.",
author = "Hong, {J. W.} and Park, {J. K.} and Lim, {C. Y.} and Kim, {S. W.} and Chung, {Y. S.} and Kim, {S. W.} and Lee, {E. J.}",
year = "2011",
month = "11",
day = "9",
doi = "10.1055/s-0031-1291246",
language = "English",
volume = "43",
pages = "956--961",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "13",

}

A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity. / Hong, J. W.; Park, J. K.; Lim, C. Y.; Kim, S. W.; Chung, Y. S.; Kim, S. W.; Lee, E. J.

In: Hormone and Metabolic Research, Vol. 43, No. 13, 09.11.2011, p. 956-961.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity

AU - Hong, J. W.

AU - Park, J. K.

AU - Lim, C. Y.

AU - Kim, S. W.

AU - Chung, Y. S.

AU - Kim, S. W.

AU - Lee, E. J.

PY - 2011/11/9

Y1 - 2011/11/9

N2 - Administration of recombinant human growth hormone (rhGH) in obesity has been known to lead to a decrease in visceral adiposity and an increase in lean body mass. Most studies have used supraphysiological doses of rhGH, which were administered daily or every other day. We aimed to evaluate whether weekly administered low dose of sustained-release rhGH (SR-rhGH) could play a therapeutic role in the treatment of abdominal obesity. Prospective, single-arm, open-label, multicenter pilot study was carried out. Participants were 26 adults aged 4065 years old with abdominal obesity (male: waist circumference >90cm, female: waist circumference >85cm). The subjects were given 3mg of SR-rhGH, administered subcutaneously, weekly for 26 weeks. SR-rhGH treatment for 26 weeks increased the IGF-1 level by 56.53±76.09g/l (SDS 0.77±1.12) compared to the baseline (p=0.0022). After 26 weeks, SR-rhGH treatment reduced abdominal visceral adipose tissue (VAT) (140.35±75.97 to 128.43±73.85cm 2, p=0.0038). Average waist circumference decreased from 96.25±6.41 to 91.93±6.13cm (p<0.0001) after treatment. However, body weight or lean body mass did not show any significant change. In conclusion, SR-rhGH treatment for 26 weeks reduced abdominal visceral fat and waist circumference without severe adverse events. Further studies may be considered on the role of weekly administered SR-rhGH as a treatment for abdominal obesity.

AB - Administration of recombinant human growth hormone (rhGH) in obesity has been known to lead to a decrease in visceral adiposity and an increase in lean body mass. Most studies have used supraphysiological doses of rhGH, which were administered daily or every other day. We aimed to evaluate whether weekly administered low dose of sustained-release rhGH (SR-rhGH) could play a therapeutic role in the treatment of abdominal obesity. Prospective, single-arm, open-label, multicenter pilot study was carried out. Participants were 26 adults aged 4065 years old with abdominal obesity (male: waist circumference >90cm, female: waist circumference >85cm). The subjects were given 3mg of SR-rhGH, administered subcutaneously, weekly for 26 weeks. SR-rhGH treatment for 26 weeks increased the IGF-1 level by 56.53±76.09g/l (SDS 0.77±1.12) compared to the baseline (p=0.0022). After 26 weeks, SR-rhGH treatment reduced abdominal visceral adipose tissue (VAT) (140.35±75.97 to 128.43±73.85cm 2, p=0.0038). Average waist circumference decreased from 96.25±6.41 to 91.93±6.13cm (p<0.0001) after treatment. However, body weight or lean body mass did not show any significant change. In conclusion, SR-rhGH treatment for 26 weeks reduced abdominal visceral fat and waist circumference without severe adverse events. Further studies may be considered on the role of weekly administered SR-rhGH as a treatment for abdominal obesity.

UR - http://www.scopus.com/inward/record.url?scp=83155180257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83155180257&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1291246

DO - 10.1055/s-0031-1291246

M3 - Article

C2 - 22072433

AN - SCOPUS:83155180257

VL - 43

SP - 956

EP - 961

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 13

ER -